Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GSR | P00390 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30565769 | 0.74 | — | — | |
| SCHEMBL14455165 | 0.74 | MAPK1 (0.44) | SMN1; SMN2MAPK1MEN1ALDH1A1LMNA | |
| SCHEMBL5602932 | 0.73 | NPC1 (0.41) | SMN1; SMN2ALDH1A1CYP1A2CYP3A4GAA | |
| SCHEMBL25297698 | 0.72 | IDO1 (0.33) | CYP1A2CYP2D6IDO1NPC1 | |
| SCHEMBL2072302 | 0.71 | CDC25B (0.39) | SMN1; SMN2MAPK1MEN1PLIN1NR1I2 | |
| SCHEMBL5602494 | 0.70 | NPC1 (0.37) | SMN1; SMN2MAPK1MEN1ALDH1A1LMNA | |
| SCHEMBL7088058 | 0.70 | — | — | |
| SCHEMBL28719124 | 0.70 | ALDH1A1 (0.32) | MAPK1ALDH1A1 | |
| SCHEMBL482253 | 0.70 | CYP1A2 (0.42) | SMN1; SMN2ALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL1404502 | 0.70 | MAPT (0.36) | SMN1; SMN2MEN1ALDH1A1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3345906-B1 | 2-ARYLAMINO PYRIDINE, PYRIDINE OR TRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | WUXI SHUANGLIANG BIOTECHNOLOGY CO LTD (CN) | 2022-05-25 | — | — | EP | claimed |
| CN-113727982-A | Azaaromatic cyclic amide derivatives for the treatment of cancer | 深圳福沃药业有限公司 | 2021-11-30 | — | — | CN | claimed |
| EP-3288933-B1 | OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | MUSC FOUND FOR RES DEV (US) | 2021-10-06 | — | — | EP | claimed |
| CN-111747950-A | Pyrimidine derivatives for the treatment of cancer | 深圳福沃药业有限公司 | 2020-10-09 | — | — | CN | claimed |
| US-10377747-B2 | 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2019-08-13 | — | — | US | claimed |
| US-20180208585-A1 | 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2018-07-26 | — | — | US | claimed |
| EP-3345906-A1 | 2-ARYLAMINO PYRIDINE, PYRIDINE OR TRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | Wuxi Shuangliang Biotechnology Co., Ltd. (CN) | 2018-07-11 | — | — | EP | claimed |
| US-20180134659-A1 | OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT | 2018-05-17 | — | — | US | claimed |
| EP-3288933-A1 | OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Musc Foundation for Research Development (US) | 2018-03-07 | — | — | EP | claimed |
| WO-2016176420-A1 | OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2016-11-03 | — | — | WO | claimed |
| US-7276567-B2 | Heterocyclic substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-10-02 | — | — | US | claimed |
| EP-1735354-A1 | HETEROCYCLIC SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | Exxonmobil Chemical Company Inc. (US) | 2006-12-27 | — | — | EP | claimed |
| US-20050261449-A1 | Heterocyclic substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENT INC. | 2005-11-24 | — | — | US | claimed |
| WO-2005105864-A1 | HETEROCYCLIC SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2005-11-10 | — | — | WO | claimed |
| US-11970474-B2 | Substituted benzodiazoles and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2024-04-30 | — | — | US | disclosed |
| CN-112074511-B | Substituted benzodiazoles and their use in therapy | 托马斯·黑勒戴药物研究基金会 | 2024-04-26 | — | — | CN | disclosed |
| CN-111747950-B | Pyrimidine derivatives for the treatment of cancer | 深圳福沃药业有限公司 | 2024-01-23 | — | — | CN | disclosed |
| EP-0765314-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-02 | — | — | EP | disclosed |
| WO-1997003070-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES HAVING CGMP-PHOSPHODISTERASE INHIBITING ACTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-01-30 | — | — | WO | disclosed |
| WO-1995034540-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208585-A1 | 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | ERBB2, EGFR, ERBB3 | SMN1; SMN2 4171/4885MAPK1 1446/4885MEN1 4741/4885 |
| US-10377747-B2 | 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof | ERBB2, EGFR, ERBB3 | SMN1; SMN2 4073/4885MAPK1 1643/4885MEN1 4741/4885 |
| US-11970474-B2 | Substituted benzodiazoles and use thereof in therapy | XDH, CYP4X1, CYP11B2 | SMN1; SMN2 1674/4885MAPK1 2175/4885MEN1 689/4885 |
| US-20180134659-A1 | OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | PARK7, OPRK1, COMT | SMN1; SMN2 110/4885MAPK1 3471/4885MEN1 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.